Nicolau DP - Search Results

1

Antimicrobial resistance: impact on clinical and economic outcomes and the need for new antimicrobials.

Thabit AK, Crandon JL, Nicolau DP. Thabit AK, et al. Among authors: nicolau dp. Expert Opin Pharmacother. 2015 Feb;16(2):159-77. doi: 10.1517/14656566.2015.993381. Epub 2014 Dec 13. Expert Opin Pharmacother. 2015. PMID: 25496207 Review.

2

Ceftibuten: an overview.

Owens RC Jr, Nightingale CH, Nicolau DP. Owens RC Jr, et al. Among authors: nicolau dp. Pharmacotherapy. 1997 Jul-Aug;17(4):707-20. Pharmacotherapy. 1997. PMID: 9250548 Review.

3

Effects of adjunctive treatment with combined cytokines in a neutropenic mouse model of multidrug-resistant Enterococcus faecalis septicemia.

Nicolau DP, Onyeji CO, Banevicius MA, Li J, Nightingale CH. Nicolau DP, et al. Pharmacotherapy. 2001 Mar;21(3):275-80. doi: 10.1592/phco.21.3.275.34209. Pharmacotherapy. 2001. PMID: 11253851

4

Clinical and economic implications of antimicrobial resistance for the management of community-acquired respiratory tract infections.

Nicolau D. Nicolau D. J Antimicrob Chemother. 2002 Sep;50 Suppl S1:61-70. doi: 10.1093/jac/dkf809. J Antimicrob Chemother. 2002. PMID: 12239229 Review.

5

Evolving epidemiology and cost of resistance to antimicrobial agents in long-term care facilities.

Capitano B, Nicolau DP. Capitano B, et al. Among authors: nicolau dp. J Am Med Dir Assoc. 2003 May-Jun;4(3 Suppl):S90-9. doi: 10.1097/01.JAM.0000066029.00660.5A. J Am Med Dir Assoc. 2003. PMID: 12854980 Review. No abstract available.

6

Pharmacokinetics of meropenem 0.5 and 2 g every 8 hours as a 3-hour infusion.

Dandekar PK, Maglio D, Sutherland CA, Nightingale CH, Nicolau DP. Dandekar PK, et al. Among authors: nicolau dp. Pharmacotherapy. 2003 Aug;23(8):988-91. doi: 10.1592/phco.23.8.988.32878. Pharmacotherapy. 2003. PMID: 12921245 Clinical Trial.

7

Optimizing outcomes with antimicrobial therapy through pharmacodynamic profiling.

Nicolau DP. Nicolau DP. J Infect Chemother. 2003 Dec;9(4):292-6. doi: 10.1007/s10156-003-0279-x. J Infect Chemother. 2003. PMID: 14691648 Review.

8

Clinical use of antimicrobial pharmacodynamic profiles to optimise treatment outcomes in community-acquired bacterial respiratory tract infections: application to telithromycin.

Nicolau DP. Nicolau DP. Expert Opin Pharmacother. 2004 Feb;5(2):229-35. doi: 10.1517/14656566.5.2.229. Expert Opin Pharmacother. 2004. PMID: 14996620 Review.

9

Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram: data collected in North America in 2002.

Kuti JL, Nightingale CH, Nicolau DP. Kuti JL, et al. Among authors: nicolau dp. Antimicrob Agents Chemother. 2004 Jul;48(7):2464-70. doi: 10.1128/AAC.48.7.2464-2470.2004. Antimicrob Agents Chemother. 2004. PMID: 15215095 Free PMC article.

10

Optimizing Efficacy in CARTIs: introduction.

Nicolau DP. Nicolau DP. Ann Pharmacother. 2004 Sep;38(9 Suppl):S7. doi: 10.1345/aph.1E216. Epub 2004 Jun 29. Ann Pharmacother. 2004. PMID: 15226491 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

763 results

Search Page

Filters